Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes

NCT05553093 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how two diabetes medications, tirzepatide and insulin glargine, affect blood sugar levels and brain function in adults with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2022-03 · est. completion 2027-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05553093 ↗

Description as written by the study sponsor.

The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.

Treatments tested

Tirzepatide also known as Tirzepatide 5、10、15mg Drug

Tirzepatide ih qw
Insulin Glargine also known as Adjust insulin dose according to fasting plasma glucose (FBG) Drug

6 IU ih qd

Main thing measured	blood sugar changes
Sponsor	Nanjing First Hospital, Nanjing Medical University
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05553093 ↗